Donar ahora Conviértase en Miembro

Carrito (0)

Already a DIA Member? Sign in. Not a member? Join.

Iniciar sesión

¿Ha olvidado su ID de usuario? or ¿Ha olvidado su contraseña?

Not a Member?

Create Account and Join

DIA Global Center

11 sep 2017 8:15 a.m. - 12 sep 2017 3:30 p.m.

21 Dupont Circle NW, Suite 300, Washington, DC 20036

Navigating Chemistry, Manufacturing, and Controls Through the Drug Development Process

Volver a Agenda

Session 5: CMC Requirements for an IND

Session Chair(s)

Albert S. Yehaskel, MBA

Albert S. Yehaskel, MBA

President and CEO

Refuah Global Pharmaceutical Development, Inc., United States

Part A: Drug Substance

Part A of the IND will discuss in detail how to design the Drug Substance portion of an IND with real examples

Part B: Drug Product

Part B of the IND will discuss in detail how to design the Drug Product portion of an IND with real examples

Part C: Placebo

Part C of the IND will discuss in detail how to design the Placebo portion of an IND in the event placebos are used in clinical trials

¿Tiene una cuenta?